JPRN-jRCT2071220049进行中（未招募）1 期
A parallel, Phase 1, randomized, open label study to evaluate the pharmacokinetics, safety and tolerability of single subcutaneous dose amlitelimab in healthy Chinese and Japanese adult participants.
Tanaka Tomoyuki0 个研究点目标入组 24 人开始时间: 2022年8月31日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 45age old（—）
- 性别
- All
入选标准
- •Chinese or Japanese male and female adult participants, between 20 and 45 years of age, inclusive, at the time of signing the informed consent.
- •- Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests.
- •- Vital signs in supine position after 10 minutes resting within the following ranges:
- •- 95 mmHg < systolic blood pressure (SBP) <140 mmHg.
- •- 45 mmHg < diastolic blood pressure (DBP) <90 mmHg.
- •- 45 bpm < heart rate (HR) <100 bpm.
- •- Body weight within the range from 50 to 100 kg and body mass index (BMI) within the range from 18-30 kg/m^2 (inclusive).
- •- Capable of giving signed informed consent includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
- •NOTE: Other Inclusion criteria may apply.
排除标准
- •Participants are excluded from the study if any of the following criteria apply:
- •Medical conditions
- •- Any history or presence of clinically relevant immunologic, cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness, unless the investigator considers an abnormality to be not clinically significant.
- •- Serious infections requiring hospitalization within 30 days prior to screening or any active or chronic infection requiring systemic treatment within 2 weeks prior to baseline (1 week in the event of superficial skin infections).
- •- Have basal or squamous cell skin cancer in the last 3 years prior to baseline. Any other malignancies not in remission within the past 5 years prior to baseline (excluding in situ cervical carcinoma that has been excised and cured).
- •- Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for vomiting only: more than twice a month).
- •Prior/concomitant therapy
- •- Any medication, with the exception of hormonal contraception, within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of the
- •medication, whichever is longer, and any biologics (antibody or its derivatives) given within 4 months before inclusion.
- •- Treatment with a live (attenuated) immunization within 12 weeks prior to IMP administration; administrations of COVID-19 vaccine within 14 days prior to IMP administration.
- •Other exclusions
- •- Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.
- •NOTE: Other Exclusion criteria may apply.
研究者
相似试验
已完成
Unknown
A parallel, Phase 1, randomized, open label study to evaluate the pharmacokinetics, safety and tolerability of single subcutaneous dose amlitelimab in healthy Chinese and Japanese adult participants.KCT0008635Sanofi-Aventis Korea24
进行中（未招募）
1 期
Pharmacokinetics, safety, and tolerability of a single-dose of SAR443765 in healthy Japanese participantsJPRN-jRCT2071220112Tanaka Tomoyuki12
进行中（未招募）
1 期
Single-dose study of SAR441344 in healthy Chinese and Japanese participantsJPRN-jRCT2071220098Tanaka Tomoyuki36
已完成
不适用
A phase 1, two-part, randomized, open-label study to evaluate the relative bioavailability and food effect of test formulations of VX-152 and Ivacaftor in healthy subjects10038686Cystic FibrosisNL-OMON43101Vertex Pharmaceuticals30
进行中（未招募）
1 期
Effect of SARS-CoV-2 Equine Antiserum Immunoglobulin (Purified F(ab)2 fragment) in hospitalised COVID-19 patients with moderate disease.CTRI/2020/11/028779Biological ELimited